Longbio Pharma

Executive Summary

Longbio Pharma is a private Chinese biotechnology company founded in 2009, headquartered in Hangzhou, with a focus on developing biologic therapeutics for oncology and autoimmune diseases. The company specializes in monoclonal antibodies and fusion proteins, leveraging capabilities from early research to cGMP manufacturing. Despite being in the preclinical stage, Longbio has established a robust platform for discovering innovative targets, though specific pipeline details are not publicly disclosed. The company's expertise in biologics positions it within the rapidly growing Chinese biotech ecosystem, but its private status and lack of clinical-stage assets limit near-term visibility. Key risks include the high failure rate of preclinical candidates and the competitive landscape for oncology and immunology targets. However, the company's long history (since 2009) suggests significant accumulated R&D experience. The conviction score reflects the early-stage nature and limited public information.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate40% success
• Q4 2026Partnership or Licensing Deal30% success
• Q1 2027Preclinical Data Release at Conference60% success